Inscription Capital LLC Acquires Shares of 13,284 AstraZeneca PLC (NASDAQ:AZN)

Inscription Capital LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,284 shares of the company's stock, valued at approximately $900,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of AZN. Bank of America Corp DE grew its position in AstraZeneca by 189.3% in the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after acquiring an additional 15,722,197 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of AstraZeneca in the fourth quarter worth approximately $254,018,000. Boston Partners lifted its stake in shares of AstraZeneca by 9,985.6% in the fourth quarter. Boston Partners now owns 3,707,479 shares of the company's stock worth $243,444,000 after acquiring an additional 3,670,719 shares during the period. Raymond James Financial Inc. acquired a new position in shares of AstraZeneca in the fourth quarter worth approximately $158,018,000. Finally, Alyeska Investment Group L.P. lifted its stake in AstraZeneca by 220.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 3,027,511 shares of the company's stock valued at $198,363,000 after buying an additional 2,083,645 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.

Analyst Upgrades and Downgrades

Separately, BNP Paribas assumed coverage on AstraZeneca in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $85.00.

AstraZeneca Stock Down 0.3%

Shares of NASDAQ:AZN traded down $0.21 during trading on Thursday, reaching $70.76. 3,370,917 shares of the stock were exchanged, compared to its average volume of 5,202,526. The stock has a fifty day moving average of $70.26 and a two-hundred day moving average of $70.38. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $87.68. The firm has a market cap of $219.45 billion, a price-to-earnings ratio of 28.42, a price-to-earnings-growth ratio of 1.30 and a beta of 0.38. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. During the same quarter in the prior year, the company posted $2.06 earnings per share. AstraZeneca's revenue was up 7.2% compared to the same quarter last year. Research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.